The Scandinavian Simvastatin Survival Study (4S) subgroup analysis of diabetic subjects: implications for the prevention of coronary heart disease.
Haffner
S M
SM
D000924:Anticholesteremic Agents / Q000627:therapeutic use; D008076:Cholesterol, HDL / Q000097:blood; D003327:Coronary Disease / Q000188:drug therapy / Q000453:epidemiology / Q000401:mortality / Q000517:prevention & control*; D003925:Diabetic Angiopathies / Q000188:drug therapy* / Q000401:mortality / Q000517:prevention & control; D015248:Gemfibrozil / Q000627:therapeutic use; D006801:Humans; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D008148:Lovastatin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D015337:Multicenter Studies as Topic; D016032:Randomized Controlled Trials as Topic; D012307:Risk Factors; D012537:Scandinavian and Nordic Countries; D019821:Simvastatin; D015996:Survival Rate; D014280:Triglycerides / Q000097:blood
D000924:Anticholesteremic Agents; D008076:Cholesterol, HDL; D000960:Hypolipidemic Agents; D014280:Triglycerides; D008148:Lovastatin; D019821:Simvastatin; D015248:Gemfibrozil